AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22269229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 250
Study 19542421 — intervention group
Group type: EXPERIMENTAL
Intervention: Flared-end stents
Number of subjects: 122
Study 19542421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bent-end stents
Number of subjects: 122
Study 17474806 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 668
Study 17474806 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg
Number of subjects: 668
Study 17474806 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg (flexible dose)
Number of subjects: 668
Study 17474806 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 668
Study 17474806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 15526245 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 40
Study 15526245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11502951 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) interventions
Number of subjects: 46
Study 11502951 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 46
Study 9380285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (105 micrograms) in addition to bupivacaine
Number of subjects: 56
Study 9380285 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 1%
Number of subjects: 56
Study 7995682 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactosamino-glycuronoglycan-sulfate (GGGS)
Number of subjects: 0
Study 7995682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3737040 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment before repeat cytology
Number of subjects: 512
Study 3737040 — intervention group
Group type: EXPERIMENTAL
Intervention: Reexamination before three months
Number of subjects: 512
Study 3737040 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who failed to revert to normal cytology on repeat examination
Number of subjects: 512
Study 3737040 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with initial cytology demonstrating marked atypia unassociated with inflammation
Number of subjects: 512
Study 3737040 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up and histologic diagnosis for 110 patients
Number of subjects: 512
Study 28852839 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1012
Study 28852839 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1012
Study 26981758 — intervention group
Group type: EXPERIMENTAL
Intervention: End-rounded bristles with dentifrice
Number of subjects: 39
Study 26981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered bristles with dentifrice
Number of subjects: 39
Study 26981758 — intervention group
Group type: EXPERIMENTAL
Intervention: End-rounded bristles without dentifrice
Number of subjects: 39
Study 26981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered bristles without dentifrice
Number of subjects: 39
Study 26981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice (used with both bristle types)
Number of subjects: 39
Study 24830716 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment group (n=49)
Number of subjects: 90
Study 24830716 — intervention group
Group type: COMPARATOR
Intervention: Case-based discussion group (control group) (n=41)
Number of subjects: 90
Study 24830716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 22323685 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised navigation TKR (group B, 98 knees)
Number of subjects: 195
Study 22323685 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKR (group A, 97 knees)
Number of subjects: 195
Study 20675027 — intervention group
Group type: EXPERIMENTAL
Intervention: Size constant stimuli
Number of subjects: 0
Study 20675027 — intervention group
Group type: COMPARATOR
Intervention: Size variable stimuli
Number of subjects: 0
Study 17900705 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (EPA+DHA) 3 g daily for 3 months
Number of subjects: 24
Study 17900705 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study 15641931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 144
Study 11895159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (enteral and parenteral)
Number of subjects: 0
Study 11895159 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12607270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (group K, n = 18)
Number of subjects: 55
Study 12607270 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (group P, n = 19)
Number of subjects: 55
Study 12607270 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen axetil (group F, n = 18)
Number of subjects: 55
Study 9419170 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 310
Study 9419170 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 310
Study 8582096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 400 mg
Number of subjects: 5
Study 8582096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2671220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (doses and concentrations traditionally used)
Number of subjects: 106
Study 939445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 2
Study 939445 — intervention group
Group type: COMPARATOR
Intervention: Non-Tourniquet (elevated hand table)
Number of subjects: 2
Study 30260794 — intervention group
Group type: COMPARATOR
Intervention: Pressure pain thresholds
Number of subjects: 42
Study 30260794 — intervention group
Group type: COMPARATOR
Intervention: Heat pain thresholds
Number of subjects: 42
Study 30260794 — intervention group
Group type: COMPARATOR
Intervention: Variability for pressure pain thresholds
Number of subjects: 42
Study 30260794 — intervention group
Group type: COMPARATOR
Intervention: Variability for heat pain thresholds
Number of subjects: 42
Study 30260794 — intervention group
Group type: COMPARATOR
Intervention: Mid-line lower range
Number of subjects: 42
Study 28431060 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 61
Study 28431060 — intervention group
Group type: COMPARATOR
Intervention: Chronic antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem (120-300 mg od)
Number of subjects: 61
Study 28431060 — intervention group
Group type: COMPARATOR
Intervention: Chronic antiarrhythmic drug (AAD) therapy
Number of subjects: 61
Study 25288674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI) 40 IU
Number of subjects: 8
Study 25288674 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (INP)
Number of subjects: 8
Study 23117071 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m² (24‐h infusion every 3 weeks)
Number of subjects: 279
Study 21762992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 872
Study 21762992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study 19132345 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA
Number of subjects: 100
Study 19132345 — intervention group
Group type: COMPARATOR
Intervention: Non-navigated TKA
Number of subjects: 100
Study 17100937 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 1057
Study 17100937 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 100 mg (2 x 50 mg encapsulated tablets)
Number of subjects: 1057
Study 15149510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol supplements
Number of subjects: 15
Study 15149510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 15
Study 11522873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous iron infusions (200 mg every 2 months)
Number of subjects: 28
Study 11522873 — intervention group
Group type: COMPARATOR
Intervention: Daily oral iron supplements (210 mg elemental iron per day)
Number of subjects: 28
Study 9050955 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (8 mg/m2 I.V. infusion every month for 1 year)
Number of subjects: 51
Study 9050955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (I.V. infusion of saline every month for 1 year)
Number of subjects: 51
Study 9050955 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 51
Study 8090084 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple sclerosis
Number of subjects: 24
Study 8090084 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study 3013033 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin precursor essential fatty acids
Number of subjects: 16
Study 30640245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (3 mg/kg)
Number of subjects: 200
Study 30640245 — intervention group
Group type: COMPARATOR
Intervention: Peritonsillar infiltration with bupivacaine (5 ml, 0.25%)
Number of subjects: 200
Study 28441325 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo training (TKD) for 60 min, 5 times per week, for 16 weeks
Number of subjects: 30
Study 28441325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TKD training)
Number of subjects: 30
Study 26643993 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 50 mg
Number of subjects: 33
Study 26643993 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 100 mg
Number of subjects: 33
Study 26643993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 26643993 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 (10 to 100 mg)
Number of subjects: 33
Study 26643993 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863
Number of subjects: 33
Study 23821414 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50 or 100 mg/day based on bodyweight) + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Number of subjects: 49
Study 23821414 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Number of subjects: 49
Study 23821414 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole + Risperidone
Number of subjects: 49
Study 21512509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% high-guluronate alginate
Number of subjects: 23
Study 21512509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% high-guluronate alginate
Number of subjects: 23
Study 21512509 — intervention group
Group type: COMPARATOR
Intervention: 0% alginate (control)
Number of subjects: 23
Study 18791776 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinex filter
Number of subjects: 29
Study 18791776 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinex filter combined with standard DICOM image
Number of subjects: 29
Study 18791776 — intervention group
Group type: COMPARATOR
Intervention: Other filters and original DICOM image
Number of subjects: 29
Study 17298708 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg phylloquinone/d
Number of subjects: 31
Study 17298708 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg phylloquinone/d
Number of subjects: 31
Study 17298708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15098518 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge, 1/2-in needle
Number of subjects: 98
Study 15098518 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge, 1 1/2-in needle
Number of subjects: 98
Study 11522145 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warm-up
Number of subjects: 8
Study 11522145 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warm-up
Number of subjects: 8
Study 11522145 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (control)
Number of subjects: 8
Study 9931699 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain service
Number of subjects: 498
Study 9931699 — intervention group
Group type: COMPARATOR
Intervention: Control group (without acute pain service)
Number of subjects: 498
Study 7923646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (0.4 mg/kg body wt bolus and 0.15 mg.kg‐1.h‐1) infused over 48 to 72 hours
Number of subjects: 302
Study 7923646 — intervention group
Group type: COMPARATOR
Intervention: Heparin (70 IU/kg body wt bolus and 15 IU.kg‐1.h‐1) infused over 48 to 72 hours
Number of subjects: 302
Study 7923646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 302
Study 7923646 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 302
Study 3347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 51
Study 3347519 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 51
Study 3347519 — intervention group
Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 51
Study 3347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive drugs or mechanical ventilation
Number of subjects: 51
Study 3347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index less than 2.3 L/min/m2
Number of subjects: 51
Study 3347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Time elapsed since surgery less than 12 hours
Number of subjects: 51
Study 3347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume
Number of subjects: 51
Study 3347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 51
Study 31634189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 4114
Study 31634189 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 4114
Study 31634189 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 4114
Study 29189022 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterattitudinal advocacy (CAA)
Number of subjects: 49
Study 29189022 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 28499707 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐SMILE (low energy: 100, 105, and 110 nJ)
Number of subjects: 151
Study 28499707 — intervention group
Group type: COMPARATOR
Intervention: C‐SMILE (conventional energy: 115‐150 nJ)
Number of subjects: 151
Study 26166077 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐MRS (1H Magnetic Resonance Spectroscopy)
Number of subjects: 60
Study 23859058 — intervention group
Group type: EXPERIMENTAL
Intervention: SoundBite
Number of subjects: 9
Study 23859058 — intervention group
Group type: COMPARATOR
Intervention: BAHI
Number of subjects: 9
Study 20881376 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (125 mg, three times/day)
Number of subjects: 36
Study 20881376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18245068 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous patient-controlled analgesia (PCA)
Number of subjects: 117
Study 18245068 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IES scores
Number of subjects: 117
Study 17001944 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgotul wound dressing with TNP therapy
Number of subjects: 66
Study 14570784 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50
Study 14570784 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50
Study 10868710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilatation
Number of subjects: 55
Study 10868710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air challenge (CACh)
Number of subjects: 55
Study 10868710 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial FEV1 (% predicted)
Number of subjects: 55
Study 10868710 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma severity and sensitization to furred animals
Number of subjects: 55
Study 8615359 — intervention group
Group type: EXPERIMENTAL
Intervention: Predigested formula A (12% linoleic acid)
Number of subjects: 76
Study 8615359 — intervention group
Group type: COMPARATOR
Intervention: Predigested formula B (7% linoleic acid)
Number of subjects: 76
Study 1598464 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid
Number of subjects: 50
Study 1598464 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid plus 75 mg dipyridamole
Number of subjects: 50
Study 1598464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 10 mg
Number of subjects: 46
Study 2856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg
Number of subjects: 46
Study 2856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg
Number of subjects: 46
Study 2856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 46
Study 2856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (all dosages)
Number of subjects: 46
Study 30160168 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAC injection
Number of subjects: 25
Study 30160168 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 25
Study 28719274 — intervention group
Group type: EXPERIMENTAL
Intervention: Never wore shoes at work
Number of subjects: 120
Study 28719274 — intervention group
Group type: EXPERIMENTAL
Intervention: Never wore shoes at home
Number of subjects: 120
Study 28719274 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed feet at day end (versus immediately after work)
Number of subjects: 120
Study 28186949 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled appointments
Number of subjects: 1087
Study 28186949 — intervention group
Group type: COMPARATOR
Intervention: Standard open reminders
Number of subjects: 1087
Study 24127249 — intervention group
Group type: EXPERIMENTAL
Intervention: Book provided during week 1
Number of subjects: 20
Study 24127249 — intervention group
Group type: COMPARATOR
Intervention: Book provided during week 4
Number of subjects: 20
Study 22350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Internet-delivered worksite health promotion programme with additional website functionalities (action-oriented feedback, self-monitoring, possibility to ask questions, monthly e-mail messages)
Number of subjects: 924
Study 22350194 — intervention group
Group type: COMPARATOR
Intervention: Standard programme consisting of a physical health check with face-to-face advice and personal feedback on a website
Number of subjects: 924
Study 19126830 — intervention group
Group type: EXPERIMENTAL
Intervention: Instalment prescription (n = 101)
Number of subjects: 204
Study 19126830 — intervention group
Group type: COMPARATOR
Intervention: Normal prescription (n = 103)
Number of subjects: 204
Study 17906248 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 43
Study 17906248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 14747671 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily iron supplementation
Number of subjects: 459
Study 14747671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) every 3 months
Number of subjects: 459
Study 14747671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iron and mebendazole
Number of subjects: 459
Study 11505342 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 49
Study 11505342 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 8993242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (group A)
Number of subjects: 19
Study 8993242 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (group B)
Number of subjects: 19
Study 8233775 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT‐CAM socket
Number of subjects: 30
Study 8233775 — intervention group
Group type: EXPERIMENTAL
Intervention: QUAD socket
Number of subjects: 30
Study 8233775 — intervention group
Group type: COMPARATOR
Intervention: Faster pace
Number of subjects: 30
Study 3113340 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful
Number of subjects: 232
Study 3113340 — intervention group
Group type: COMPARATOR
Intervention: UFT
Number of subjects: 232
Study 31588801 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach total hip arthroplasty (DA THA)
Number of subjects: 111
Study 31588801 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach total hip arthroplasty
Number of subjects: 111
Study 29396897 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based brief intervention (IBI)
Number of subjects: 626
Study 29396897 — intervention group
Group type: COMPARATOR
Intervention: Control (assessment only)
Number of subjects: 626
Study 27181129 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on TCM diagnosis
Number of subjects: 0
Study 27181129 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 25070111 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine treatment
Number of subjects: 126
Study 23354913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care treatment
Number of subjects: 293
Study 23354913 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy
Number of subjects: 293
Study 20826525 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 19°C
Number of subjects: 25
Study 18461650 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 1404
Study 18461650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study 15879586 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (olanzapine, perospirone, quetiapine, or risperidone)
Number of subjects: 86
Study 12939003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdenture (IOD)
Number of subjects: 63
Study 12939003 — intervention group
Group type: COMPARATOR
Intervention: Mandibular conventional denture (CD)
Number of subjects: 63